drugset / Trial / NCT01915134
Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma
Phase 3
Unknown
362 enrolled
Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University · collabSir Run Run Shaw Hospital · collabZhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
Timeline
- Start
- 2013-08
- Primary completion
- 2016-01
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |